title: Recurrent status epilepticus in children.
abstract: Status epilepticus is an uncommon but life-threatening seizure. Little is known about the risk of recurrent status epilepticus in patients who present with an initial episode. To determine the risk of recurrent status epilepticus in children, we prospectively followed 95 children, identified at the time of their first episode of status epilepticus, for a mean of 29.0 months (range, 4-60 months). The patients' ages ranged from 1 month to 18 years (mean, 4.6 years). The cause of the status epilepticus was classified as idiopathic (n = 24), remote symptomatic (n = 18), febrile (n = 29), acute symptomatic (n = 18), or progressive neurological disorder (n = 6). Sixteen children (17%) had at least 2 episodes of status epilepticus. The risk of recurrent status was 4% (n = 1) in the idiopathic group, 44% (n = 8) in the remote symptomatic group, 3% (n = 1) in the febrile group, 11% (n = 2) in the acute symptomatic group, and 67% (n = 4) in those with progressive neurological disease. Recurrent status epilepticus occurred primarily in neurologically abnormal children. While neurologically abnormal children accounted for 34% (n = 32) of all children with status epilepticus, they comprised 88% (n = 14) of the children with recurrent status epilepticus (p less than 0.001) and all 5 of the children with multiple (greater than or equal to 3) episodes of status (p less than 0.001). Fifteen of 16 children with recurrent status epilepticus were being treated with antiepileptic drugs at the time of recurrence. The morbidity and mortality of status epilepticus were low.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Neurology, Albert Einstein College of Medicine, Bronx, NY.
authors.forename: S
authors.initials: S
authors.lastname: Shinnar
authors.forename: J
authors.initials: J
authors.lastname: Maytal
authors.forename: L
authors.initials: L
authors.lastname: Krasnoff
authors.forename: S L
authors.initials: SL
authors.lastname: Moshe
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use; D001927:Brain Diseases / Q000150:complications; D002547:Cerebral Palsy / Q000150:complications / Q000453:epidemiology; D002675:Child, Preschool; D015331:Cohort Studies; D005006:Ethnicity; D005260:Female; D006801:Humans; D007223:Infant; D008607:Intellectual Disability / Q000453:epidemiology / Q000209:etiology; D015993:Life Tables; D008297:Male; D009422:Nervous System Diseases / Q000150:complications / Q000453:epidemiology / Q000401:mortality; D011446:Prospective Studies; D012008:Recurrence; D012306:Risk; D003294:Seizures, Febrile / Q000150:complications; D013226:Status Epilepticus / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology
chemical_list: D000927:Anticonvulsants